These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
171 related articles for article (PubMed ID: 22951414)
1. Heterotypic three-dimensional in vitro modeling of stromal-epithelial interactions during ovarian cancer initiation and progression. Lawrenson K; Grun B; Gayther SA J Vis Exp; 2012 Aug; (66):e4206. PubMed ID: 22951414 [TBL] [Abstract][Full Text] [Related]
2. Senescent fibroblasts promote neoplastic transformation of partially transformed ovarian epithelial cells in a three-dimensional model of early stage ovarian cancer. Lawrenson K; Grun B; Benjamin E; Jacobs IJ; Dafou D; Gayther SA Neoplasia; 2010 Apr; 12(4):317-25. PubMed ID: 20360942 [TBL] [Abstract][Full Text] [Related]
3. Modelling genetic and clinical heterogeneity in epithelial ovarian cancers. Lawrenson K; Sproul D; Grun B; Notaridou M; Benjamin E; Jacobs IJ; Dafou D; Sims AH; Gayther SA Carcinogenesis; 2011 Oct; 32(10):1540-9. PubMed ID: 21859834 [TBL] [Abstract][Full Text] [Related]
4. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients. Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906 [TBL] [Abstract][Full Text] [Related]
5. Identification of ribonucleotide reductase M2 as a potential target for pro-senescence therapy in epithelial ovarian cancer. Aird KM; Li H; Xin F; Konstantinopoulos PA; Zhang R Cell Cycle; 2014; 13(2):199-207. PubMed ID: 24200970 [TBL] [Abstract][Full Text] [Related]
6. Isolation and characterization of stromal progenitor cells from ascites of patients with epithelial ovarian adenocarcinoma. Ho CM; Chang SF; Hsiao CC; Chien TY; Shih DT J Biomed Sci; 2012 Feb; 19(1):23. PubMed ID: 22330345 [TBL] [Abstract][Full Text] [Related]
7. Stromal-epithelial interactions in the progression of ovarian cancer: influence and source of tumor stromal cells. Parrott JA; Nilsson E; Mosher R; Magrane G; Albertson D; Pinkel D; Gray JW; Skinner MK Mol Cell Endocrinol; 2001 Apr; 175(1-2):29-39. PubMed ID: 11325514 [TBL] [Abstract][Full Text] [Related]
8. Orthotopic, syngeneic mouse model to study the effects of epithelial-stromal interaction. Greenaway JB; Petrik JJ Methods Mol Biol; 2013; 1049():409-23. PubMed ID: 23913234 [TBL] [Abstract][Full Text] [Related]
9. Defective expression of Protein 4.1N is correlated to tumor progression, aggressive behaviors and chemotherapy resistance in epithelial ovarian cancer. Xi C; Ren C; Hu A; Lin J; Yao Q; Wang Y; Gao Z; An X; Liu C Gynecol Oncol; 2013 Dec; 131(3):764-71. PubMed ID: 23994105 [TBL] [Abstract][Full Text] [Related]
11. Wnt5a suppresses epithelial ovarian cancer by promoting cellular senescence. Bitler BG; Nicodemus JP; Li H; Cai Q; Wu H; Hua X; Li T; Birrer MJ; Godwin AK; Cairns P; Zhang R Cancer Res; 2011 Oct; 71(19):6184-94. PubMed ID: 21816908 [TBL] [Abstract][Full Text] [Related]
12. Syndecan-1 serves as a marker for the progression of epithelial ovarian carcinoma. Guo Q; Yang X; Ma Y; Ma L Eur J Gynaecol Oncol; 2015; 36(5):506-13. PubMed ID: 26513873 [TBL] [Abstract][Full Text] [Related]
13. Feto-maternal outcomes of pregnancy complicated by epithelial ovarian cancer: a systematic review of literature. Blake EA; Kodama M; Yunokawa M; Ross MS; Ueda Y; Grubbs BH; Matsuo K Eur J Obstet Gynecol Reprod Biol; 2015 Mar; 186():97-105. PubMed ID: 25668134 [TBL] [Abstract][Full Text] [Related]
14. Cancer-associated fibroblasts and their putative role in potentiating the initiation and development of epithelial ovarian cancer. Schauer IG; Sood AK; Mok S; Liu J Neoplasia; 2011 May; 13(5):393-405. PubMed ID: 21532880 [TBL] [Abstract][Full Text] [Related]
15. Stromal-epithelial crosstalk provides a suitable microenvironment for the progression of ovarian cancer cells in vitro. Fu S; Dong L; Sun W; Xu Y; Gao L; Miao Y Cancer Invest; 2013 Nov; 31(9):616-24. PubMed ID: 24147897 [TBL] [Abstract][Full Text] [Related]
16. Genetic determinants of FOXM1 overexpression in epithelial ovarian cancer and functional contribution to cell cycle progression. Barger CJ; Zhang W; Hillman J; Stablewski AB; Higgins MJ; Vanderhyden BC; Odunsi K; Karpf AR Oncotarget; 2015 Sep; 6(29):27613-27. PubMed ID: 26243836 [TBL] [Abstract][Full Text] [Related]
17. Interaction between Treg cells and tumor-associated macrophages in the tumor microenvironment of epithelial ovarian cancer. Zhu Q; Wu X; Wu Y; Wang X Oncol Rep; 2016 Dec; 36(6):3472-3478. PubMed ID: 27748885 [TBL] [Abstract][Full Text] [Related]
18. Overexpression of Semaphorin4D indicates poor prognosis and prompts monocyte differentiation toward M2 macrophages in epithelial ovarian cancer. Chen Y; Zhang L; Lv R; Zhang WQ Asian Pac J Cancer Prev; 2013; 14(10):5883-90. PubMed ID: 24289594 [TBL] [Abstract][Full Text] [Related]
19. Ovarian cancer-associated fibroblasts contribute to epithelial ovarian carcinoma metastasis by promoting angiogenesis, lymphangiogenesis and tumor cell invasion. Zhang Y; Tang H; Cai J; Zhang T; Guo J; Feng D; Wang Z Cancer Lett; 2011 Apr; 303(1):47-55. PubMed ID: 21310528 [TBL] [Abstract][Full Text] [Related]
20. Overexpression of epithelial macrophage colony-stimulating factor (CSF-1) and CSF-1 receptor: a poor prognostic factor in epithelial ovarian cancer, contrasted with a protective effect of stromal CSF-1. Chambers SK; Kacinski BM; Ivins CM; Carcangiu ML Clin Cancer Res; 1997 Jun; 3(6):999-1007. PubMed ID: 9815777 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]